According to numerous studies, the high expression of CIP2A/p90 in some cancers, such as cutaneous melanoma, breast cancer, colon cancer, cervical cancer, prostate cancer, and oral cancer, is associated with pathologic high-grade tumor and the progression of disease (Côme et al., 2009; Vaarala et al., 2010; Böckelman et al., 2011a; Böckelman et al., 2012; Shi et al., 2014; Velmurugan et al., 2019). Here, CIP2A is linked to prostate carcinoma.